The role of innovation in drug development

Nature Biotechnology

Volumn 15, Issue 13, 1997, Pages 1318-1319

  Drews, Jürgen ^a   Ryser, Stefan ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; DRUG DESIGN; ECONOMICS; GENOME; HUMAN; LEGAL ASPECT; PHARMACEUTICS; PHARMACOGENETICS; PHARMACOLOGY; RESEARCH;

COST-BENEFIT ANALYSIS; DRUG DESIGN; GENOME; HUMANS; PHARMACOGENETICS; PHARMACOLOGY; RESEARCH; TECHNOLOGY, PHARMACEUTICAL;

EID: 0031304155     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1297-1318     Document Type: Note

References (7)

1. Human disease—From genetic causes to biochemical effects. Proceedings of the Roche Symposium “The Genetic Basis of Human Disease”, October 2-3, 1996, Basel. Drews, J. and Ryser, S. (eds.) Ex Libris Roche 9. Blackwell Science, Berlin.
2. Lifton, R. Human disease—From genetic causes to biochemical effects. Proceedings of the Roche Symposium “The Genetic Basis of Human Disease”, October 2-3, 1996, Basel. Drews, J. and Ryser, S. (eds.) Ex Libris Roche 9. Blackwell Science, Berlin.
3. Weber, W. 1997. pp. 10-11 in Pharmacogenetics. Oxford Univ. Press, New York and Oxford.
4. Ohsako, S. and Deguchi, T. 1990. J. Biol. Chem. 265:4630-4634.
5. Weber, W. 1997. pp. 12-13 in Pharmacogenetics. Oxford Univ. Press, New York and Oxford.
6. Mossinghoff, G.J. 1995. Drug Info. J. 29:1077-1090.
7. Drews, J. and Ryser, S. 1997. Drug Discovery Today 2:365-372.